Table 3.
PCV7 and PCV13 serotype distribution by patient demographics among isolates from patients with a positive S. pneumoniae isolate.
| Age Group, y | Risk | Pneumonia | ||||||
| |
50–<65 |
65–<80 |
≥80 |
High risk |
At risk |
None |
HCAP |
CAP |
| Positive isolates (any test),a n | 20 | 38 | 22 | 33 | 36 | 11 | n/a | n/a |
| Positive isolates (UAD/culture),b n | 16 | 25 | 13 | 22 | 25 | 7 | 12 | 42 |
| Total vaccine serotypesc, n (%) | 10 | 18 | 10 | 12 | 21 | 5 | 7 | 31 |
| Serotypes covered in PCV7, n (%) | ||||||||
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 6B | 1 (6.3) | 0 (0.0) | 1 (7.7) | 1 (4.5) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 2 (4.8) |
| 9V | 0 (0.0) | 1 (4.0) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
| 14 | 0 (0.0) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (2.4) |
| 18C | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 19F | 0 (0.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 1 (2.4) |
| 23F | 5 (31.3) | 2 (8.0) | 0 (0.0) | 1 (4.5) | 6 (24.0) | 0 (0.0) | 1 (8.3) | 6 (14.3) |
| Total PCV7 serotypes, n (%) | 6 | 4 | 2 | 3 | 7 | 2 | 2 | 10 |
| 6 additional serotypes in PCV13, n (%) | ||||||||
| 1 | 1 (6.3) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (4.0) | 1 (14.3) | 0 (0.0) | 2 (4.8) |
| 3 | 1 (6.3) | 8 (32.0) | 3 (23.1) | 4 (18.2) | 6 (24.0) | 2 (28.6) | 0 (0.0) | 12 (28.6) |
| 5 | 0 (0.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 2 (8.0) | 0 (0.0) | 1 (8.3) | 1 (2.4) |
| 6A | 1 (6.3) | 0 (0.0) | 2 (15.4) | 2 (9.1) | 1 (4.0) | 0 (0.0) | 1 (8.3) | 2 (4.8) |
| 7F | 1 (6.3) | 1 (4.0) | 0 (0.0) | 1 (4.5) | 1 (4.0) | 0 (0.0) | 1 (8.3) | 1 (2.4) |
| 19A | 0 (0.0) | 2 (8.0) | 3 (23.1) | 2 (9.1) | 3 (12.0) | 0 (0.0) | 2 (16.7) | 3 (7.1) |
| Total additional PCV13 serotypes, n (%) | 4 | 14 | 8 | 9 | 14 | 3 | 5 | 21 |
| Total non-PCV13 isolates (any test), an | 10 | 20 | 12 | 21 | 15 | 6 | n/a | n/a |
| Typed non-PCV13 related serotypes,dn | 6 | 4 | 3 | 9 | 2 | 2 | 3 | 10 |
CAP = community-associated pneumonia; HCAP = healthcare-associated pneumonia; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; UAD = urinary antigen detection.
a
Number of isolates identified from Binax, UAD or culture.
b
Number of isolates identified from UAD or culture. The values in this row are used as denominators for percentages of individual serotype isolates.
c
Identified from UAD and/or culture.
d
Identified from culture only.